Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival.

doi:10.1016/j.ejca.2024.113583

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2024

Pire Aurore, Hirsch Theo Z, Morcrette Guillaume, Imbeaud Sandrine, Gupta Barkha, Pilet Jill, Cornet Marianna, Fabre Monique, Guettier Catherine, Branchereau Sophie, Brugières Laurence, Guerin Florent, Laithier Véronique, Coze Carole, Nagae Genta, Hiyama Eiso, Laurent-Puig Pierre, Rebouissou Sandra, Sarnacki Sabine, Chardot Christophe, Capito Carmen, Faure-Conter Cécile, Aerts Isabelle, Taque Sophie, Fresneau Brice, Zucman-Rossi Jessica

Abstract excerpt

BACKGROUND: Hepatoblastoma is the most frequent pediatric liver cancer. The current treatments lead to 80% of survival rate at 5 years. In this study, we evaluated the clinical relevance of molecular features to identify patients at risk of chemoresistance, relapse and death of disease. METHODS: All the clinical data of 86 children with hepatoblastoma were retrospectively collected. Pathological slides were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Profiling

Share to Genetic and Kidney Cyst Diseases

Share to Hepatoblastoma

Share to Hepatocellular Carcinoma Treatment and Prognosis

Share to Liver Neoplasms

Share to Mutation

Share to Neoplasm Recurrence, Local

Source

Open in PubMed

Identifiers

PMID: 38330765
DOI: 10.1016/j.ejca.2024.113583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival.PMID 38330765Read ↗

Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer.Semantic proximity Read ↗

Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroupsSemantic proximity Read ↗

Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy.Semantic proximity Read ↗

Hepatoblastoma: current understanding, recent advances, and controversiesSemantic proximity Read ↗

Biology of childhood hepatoblastoma and the search for novel treatmentsSemantic proximity Read ↗

General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.Semantic proximity Read ↗

The genomic landscape of hepatoblastoma and their progenies with HCC-like features.Semantic proximity Read ↗

Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targetsSemantic proximity Read ↗

Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.Semantic proximity Read ↗

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implicationsSemantic proximity Read ↗

Genetic and epigenetic basis of hepatoblastoma diversity.Semantic proximity Read ↗

Single‐cell transcriptomics uncovers cellular architecture and developmental trajectories in hepatoblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.